Fierce Competition Podcast | Antitrust Collusion in Labor Markets: Enforcement Trends on Both Sides of the Atlantic
Daily Compliance News: July 29, 2025 the Is CEO Conduct Ever Personal Edition
The LathamTECH Podcast — Getting Deals Done: Tackling Antitrust Challenges in Tech M&A
10 For 10: Top Compliance Stories For the Week Ending April 26, 2025
Daily Compliance News: April 24, 2025, The Made in Malaysia Edition
AGG Talks: Healthcare Insights Podcast - Episode 7: National MultiPlan Litigation: A Guide for Healthcare Providers
12 Days of Regulatory Insights: Day 11 – State AGs on the Antitrust Frontline — Regulatory Oversight Podcast
Daily Compliance News: November 15, 2024 - The Meta Fined (again) Edition
Antitrust Considerations in Long-Term Care — Assisted Living and the Law Podcast
Episode 323 - Carlos Villagran Discusses Rebuilding a Corporate Culture After a Crisis
The Changing Landscape of State AG Antitrust Enforcement — Regulatory Oversight Podcast
AGG Talks: Antitrust and White-Collar Crime Roundup - Analyzing the Latest Updates in the Litigation Against Trump
Fierce Competition Podcast | Letter From London: The Rise of UK Class Actions and the Competition Appeal Tribunal
JONES DAY TALKS® - Charting the Course: Antitrust's Past, Present, and Future in Labor Markets
State AG Pulse | America’s Pastime Unites AGs
The Presumption of Innocence Podcast: Episode 18 - A Deep Dive Into Antitrust Violations and the Procurement Collusion Strike Force
Class Action | Eleventh Circuit Reinstates No Hire Antitrust Claims Against Burger King
Antitrust Conversations: Fundamentals of Antitrust Law
How Antitrust Regulators and the SEC Are Advancing the Wider Biden Agenda
Taking the Pulse, A Health Care and Life Sciences Podcast | Episode 100: Marguerite Willis, Nexsen Pruet Attorney
On 4 July 2025, the EC fined Alchem and its subsidiary EUR 489,000 for their role in a long-running cartel concerning the active pharmaceutical ingredient SNBB, used in the production of Buscopan and its generics. This marks...more
In the European Union, Big Pharma has been operating with a target on its back for the best part of the last decade. Following its 2008 sector inquiry into the pharmaceutical sector, the Commission vowed to clamp down on...more